Genome-wide methylation analysis of circulating cell-free DNA identifies an episignature in lung cancer: validation of EMP2 as a potential biomarker
Our findings support the utility of methylome-wide cfDNA profiling for LC biomarker discovery. EMP2 promoter methylation represents a promising candidate for the minimally invasive detection of LC across heterogeneous clinical presentations.
Authors
- David Hervás (ORCID: https://orcid.org/0000-0003-0635-4961)
- Óscar Juan (ORCID: https://orcid.org/0000-0002-7772-9030)
- Alfonso Calvo (ORCID: https://orcid.org/0000-0003-4074-4242)
- José M. Galbis (ORCID: https://orcid.org/0000-0002-1058-0171)
- Raquel Martínez-Tomás
- Ester Alemany-Cosme (ORCID: https://orcid.org/0000-0001-5037-472X)
- Cora Palanca-Ballester (ORCID: https://orcid.org/0000-0002-4520-1514)
- Juan Sandoval (ORCID: https://orcid.org/0000-0002-5100-973X)
- Agustín Lahoz (ORCID: https://orcid.org/0000-0001-7232-0626)
- Andrés Briones-Gómez
- Dario Alexander Cruz-Chamorro
- Diana Garcia (ORCID: https://orcid.org/0000-0003-3588-1680)
- Enrique Cases
Institutions
- Hospital Universitari i Politècnic La Fe (ES)
- Hospital de La Ribera (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Instituto de Investigación Sanitaria La Fe (ES)
- Universitat Politècnica de València (ES)
- Epigenomics (Germany) (DE)
- Universidad de Navarra (ES)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1186/s13148-025-02026-4
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.00